

Appl. No. 09/778,187

Docket No. 2873-US-NP

## 2. Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-19 (Canceled)

20. (Currently amended) An isolated polypeptide comprising ~~an amino acid sequence that is at least 90% identical to~~ amino acids  $X_1$  to  $X_2$  as shown in SEQ ID NO: 2 wherein  $X_1$  is 1 or 39 and  $X_2$  is 374 or 442, said isolated polypeptide being capable of binding to a LDCAM polypeptide of SEQ ID NO: 2 or SEQ ID NO: 4, a B7L-1 polypeptide of SEQ ID NO: 8 or SEQ ID NO: 10, or both.

21. (Previously presented) The isolated polypeptide according to Claim 20, wherein  $X_2$  is 374.

22. (Currently amended) An isolated polypeptide selected from the group consisting of:

- (a) a polypeptide comprising amino acids  $X_1$  to  $X_2$  as shown in SEQ ID NO: 2, wherein  $X_1$  is 1 or 39 and  $X_2$  is 374 or 442;
- (b) a polypeptide comprising amino acids  $X_3$  to  $X_4$  as shown in SEQ ID NO: 4, wherein  $X_3$  is 1 or 21 and  $X_4$  is 356 or 423; and
- (c) a polypeptide comprising a fragment of amino acids  $X_1$  to  $X_2$  in (a) or  $X_3$  to  $X_4$  in (b), wherein said fragment has 1 to 5 amino acids removed from either the amino or carboxy terminus of amino acids 39-374 of SEQ ID NO: 2 or amino acids 21-356 of SEQ ID NO: 4;

said isolated polypeptide being capable of binding to a LDCAM polypeptide of SEQ ID NO: 2 or SEQ ID NO: 4, a B7L-1 polypeptide of SEQ ID NO: 8 or SEQ ID NO: 10, or both.

23. (Currently amended) The isolated polypeptide according to Claim 22 comprising amino acids  $X_1$  to  $X_2$  as shown in SEQ ID NO: 2 or a fragment of said amino acids, wherein  $X_1$  is 1 or 39 and  $X_2$  is 374 or 442, wherein said fragment has 1

Appl. No. 09/778,187

Docket No. 2873-US-NP

to 5 amino acids removed from either the amino or carboxy terminus of amino acids 39-374 of SEQ ID NO: 2.

24. (Previously presented) The isolated polypeptide according to Claim 23 wherein  $X_2$  is 374.

25. (Previously presented) The isolated polypeptide according to Claim 23 wherein  $X_2$  is 442.

26. (Currently amended) The isolated polypeptide according to Claim 22 comprising amino acids  $X_3$  to  $X_4$  as shown in SEQ ID NO: 4 or a fragment of said amino acids, wherein  $X_3$  is 1 or 21 and  $X_4$  is 356 or 423, wherein said fragment has 1 to 5 amino acids removed from either the amino or carboxy terminus of amino acids 21-356 of SEQ ID NO: 4.

27. (Previously presented) The isolated polypeptide according to Claim 26 wherein  $X_4$  is 356.

28. (Previously presented) The isolated polypeptide according to Claim 26 wherein  $X_4$  is 423.

29. (Currently amended) The isolated polypeptide according to Claim ~~23~~24 or ~~26~~27 that is soluble.

30. (Currently amended) A fusion polypeptide comprising the polypeptide according to Claim ~~22~~20.

31. (Previously presented) The fusion polypeptide according to Claim 30, wherein said fusion polypeptide comprises a Fc region, or a peptide linker, or a Fc region and a peptide liker.

32. (Currently amended) An oligomer comprising the polypeptide according to Claim ~~22~~20.

Appl. No. 09/778,187

Docket No. 2873-US-NP

33. (Previously presented) The oligomer according to Claim 32 which is a dimer, a trimer, or a tetramer.

34. (Currently amended) A composition comprising the polypeptide according to Claim ~~2220~~ and a suitable carrier.

35-63. (Cancelled)